Senator Amy Klobuchar has raised concerns over possible collusion in healthcare pricing, urging federal regulators to investigate the role of data analytics firm MultiPlan in facilitating alleged price fixing among major health insurers. This comes following a recent report by the New York Times shedding light on MultiPlan’s influence in the pricing of out-of-network medical claims.
In a letter addressed to the heads of the Justice Department’s antitrust division and the Federal Trade Commission, Senator Klobuchar emphasized the need to examine whether MultiPlan’s algorithms have enabled insurers to conspire in reducing payments to doctors, potentially leading to higher bills for patients. She argued that algorithms should enhance decision-making accuracy and efficiency, not enable collusion to the detriment of patients.
MultiPlan, a significant player in the healthcare industry, provides pricing recommendations for out-of-network medical claims, often resulting in reduced payments to providers. According to reports, this practice allows MultiPlan and its partner insurers to increase their profits, albeit at the expense of patients who may face higher bills due to unpaid balances.
Major insurers such as UnitedHealthcare, Cigna, and Aetna rely on MultiPlan’s pricing recommendations, with the firm boasting its integral role in clients’ claims-processing systems to investors. Critics argue that this arrangement could potentially amount to price fixing, as insurers may opt to follow MultiPlan’s low pricing recommendations rather than competing to offer better coverage.
Experts in antitrust law, including Barak Orbach from the University of Arizona, have echoed concerns, suggesting that the situation warrants investigation by regulatory agencies. Orbach highlighted the apparent strength of the case against MultiPlan and its partners, emphasizing the need for thorough scrutiny.
Source: NY Times
Featured News
US Judge OKs $110 Million Settlements in Antitrust Case Against Major Real Estate Brokerages
Oct 31, 2024 by
CPI
50 States and Territories Reach $49.1 Million Settlement in Generic Drug Price-Fixing Case
Oct 31, 2024 by
CPI
OpenAI Enhances ChatGPT with New Search Feature, Challenging Google’s Dominance
Oct 31, 2024 by
CPI
First Circuit Hears Arguments on Whether Federal Baseball Antitrust Exemption Shields Puerto Rican League from Legal Claims
Oct 31, 2024 by
CPI
Federal Appeals Court Expresses Doubts Over FCC’s Authority in Net Neutrality Revival
Oct 31, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI